Biomarkers in Cancer Detection and Monitoring of Therapeutics

Professor Sobti is an Education Consultant Governor of Bihar and Senior Scientist at the Indian National Science Academy, in addition to Former Vice Chancellor at Babasaheb Bhimrao Ambedkar University, Lucknow, and Panjab University, Chandigarh, India. Beginning his career as a Cytogeneticist, Professor Sobti moved on to explore the role of gene polymorphisms and their expression in the genesis of various cancers, COPD, AIDS and metabolic syndrome. He has identified disease susceptible / protective novel genotypes and determined the crucial role of SACS-1 and STAT genes in the genesis of cervical and prostate cancers. He has contributed to 270 research publications, 35 books and 23 sponsored research projects. He has received prestigious awards and medals, including the honor of “Padma Shri” from the Government of India for his contribution to higher education. Additionally he was honored with ‘Bharat Gaurav’, Lifetime Achievement Award at the House of Commons, British Parliament, London, UK. Dr. Awtar Krishan PhD is a world-renowned scientist. He obtained his PhD from Panjab University (1962) and the Univ. of Western Ontario, Canada (1963) in Cytogenetics and Anatomy. From 1965 to 1977, he was at the Sidney Farber Cancer Institute, Harvard Medical School as Head of the Tissue Ultrastructure and Experimental Pathology Labs. He has developed flow cytometric techniques for rapid analysis of DNA content by hypotonic propidium iodide, monitoring of drug retention and resistance, and more recently for monitoring hormone receptor expression in archival tumors. He is currently Director, Analytical Cytometry Laboratory, at University of Miami. Aastha Sobti is a Doctoral student at the Department of Immunotechnology at Lund University, Sweden. Her research areas interests include translational medicine, clinical dentistry, cancer immunology, biomarkers, diagnostics and medical oncology. Aastha Sobti has written two books with Elsevier: "Biomarkers in Cancer Detection and Monitoring of Therapeutics" (2023) and Molecular Medicine and Biomedical Research in the Era of Precision Medicine (2025).

1. CANCER BURDEN: EPIDEMIOLOGY, RACIAL AND GEOGRAPHICAL DISPARITIES
Shaveta Menon and Ramila Bisht
2. MILESTONES IN CANCER RESEARCH
Siddharth Sharma
3. TECHNOLOGICAL EVOLUTION IN CANCER DIAGNOSISAND THERAPEUTICS
Sudeep Bose I
4. HOW DOES TIME SPEAK ABOUT CANCER, ITS DIAGNOSIS, TREATMENTS AND CHALLENGES?
Asit Ranjan Ghosh
5. ROLE OF ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS AND THERAPEUTICS
B. Medhi
6. ADDRESSING THE DIAGNOSIS AND THERAPEUTICS OF MALIGNANT TUMOUR CELLS
Anjoy Mahji
7. SOMATIC MUTATION: PHARMACOGENOMICS IN ONCOLOGY CARE
Shamsher Singh
8. INSIGHTS INTO GENETIC PREDISPOSITION OF SOMATIC CANCERS
B. Medhi
9. THE USE OF TUMOR MARKERS IN PROGNOSIS OF CANCER AND STRATEGIES TO PREVENT CANCER PREDISPOSITION AND PROGRESS
Osama Ahmed, Mohamed Abd-Elbaset, Noha Ahmed and Eman Abd Elhaliem
10. CYTOGENETICS TO MULTI-OMICS IN BIOLOGY OF CANCER
Sikander S. Gill
11. ROLE OF NON-CODING RNA AS BIOMARKERS FOR CANCER
Bikash Medhi and B. Medhi
12. VIRAL miRNA's: DIAGNOSTIC AND PROGNOSTIC BIOMARKERS FOR CANCER AND INFECTIOUS DISEASE
Sunil Babu Gosipatala, Dr. Abhishek Pandeya, Raj Kumar Khalko, Ranbir C. Sobti Sr., Sneha Kumari, Prashansa Khanna and Utkarsha Vishwakarma
13. PHARMACOGENOMICS AND ONCOLOGY: A THERAPEUTIC APPROACH FOR CANCER TREATMENT
Shamsher Singh and Anil Kumar
14. ENVIRONMENTAL FACTORS INFLUENCING EPIGENETIC CHANGES INITIATING NEOPLASTIC CHANGES
B. Medhi
15. OBESITY: EMERGING RISK FACTOR FOR CANCER BEYOND METABOLIC SYNDROME
Ranbir C. Sobti Sr.
16. HOMOLOGOUS REPAIR DEFICIENCY AND PARP INHIBITORS IN CANCER MANAGEMENT
Shivani Arora Mittal
17. MOLECULAR PROSPECTS OF TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES (TALENS) IN CANCER
Mani Chopra
18. IMMUNO PEPTIDOMIC APPROACHES FORMANAGEMENT OFCANCER
B. Medhi
19. REGULATION OF TUMOR MICROENVIRONMENT BY NUTRIENT TRAFFICKING
B. Medhi
20. PRECISION MEDICINE : DOSE FOR ANTI CANCER THERAPY
Dr Shiva Tushir